Fig. 3 (abstract 06).From: 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2Anti-CSF1R treatment leads to delayed B2M-KO tumor growthBack to article page